LOW DOSE REGIMEN AND FORMULATION OF A 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUND

ABSTRACT The present invention provides a compound of Formula I:, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day, useful for treating a ne...

Full description

Saved in:
Bibliographic Details
Main Authors MERGOTT, DUSTIN JAMES, KIELBASA, WILLIAM BRIAN
Format Patent
LanguageEnglish
French
Published 27.01.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:ABSTRACT The present invention provides a compound of Formula I:, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day, useful for treating a neurodegenerative disease, including neurodengenerative tauopathies, such as Alzheimers disease, frontotemporal dementia, corticobasilar syndrome, and progressive supranuclear palsy. La présente invention concerne un composé de formule I : ou un sel pharmaceutiquement acceptable de celui-ci, le composé de formule I, ou un sel pharmaceutiquement acceptable de celui-ci étant administré par voie orale avec une dose totale du composé de 0,1 mg/jour à 5 mg/jour, utile pour le traitement d'une maladie neurodégénérative, y compris des tauopathies neurodégénératives, telles que la maladie d'alzheimer, la démence frontotemporale, le syndrome corticobasilaire et la paralysie supranucléaire progressive.
Bibliography:Application Number: CA20213186808